Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 141800.0
(1.29%)
KRW 141800.0
(1.29%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 53.62 Billion KRW | -29.98% |
| 2022 | 76.59 Billion KRW | 48.6% |
| 2021 | 51.54 Billion KRW | 90.37% |
| 2020 | 27.07 Billion KRW | 13.51% |
| 2019 | 23.85 Billion KRW | 18.35% |
| 2018 | 20.15 Billion KRW | 277.69% |
| 2017 | 5.33 Billion KRW | -23.54% |
| 2016 | 6.97 Billion KRW | 50.71% |
| 2015 | 4.63 Billion KRW | -9.8% |
| 2014 | 5.13 Billion KRW | -70.15% |
| 2013 | 17.19 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 54 Billion KRW | 1.02% |
| 2024 Q1 | 53.45 Billion KRW | -0.31% |
| 2023 Q2 | 85.18 Billion KRW | 0.58% |
| 2023 Q1 | 84.69 Billion KRW | 10.58% |
| 2023 FY | 53.62 Billion KRW | -29.98% |
| 2023 Q4 | 53.62 Billion KRW | -24.87% |
| 2023 Q3 | 71.37 Billion KRW | -16.21% |
| 2022 Q4 | 76.59 Billion KRW | 0.19% |
| 2022 FY | 76.59 Billion KRW | 48.6% |
| 2022 Q3 | 76.44 Billion KRW | 0.43% |
| 2022 Q2 | 76.11 Billion KRW | 5.42% |
| 2022 Q1 | 72.19 Billion KRW | 40.08% |
| 2021 Q3 | 51.9 Billion KRW | 1.11% |
| 2021 Q4 | 51.54 Billion KRW | -0.69% |
| 2021 FY | 51.54 Billion KRW | 90.37% |
| 2021 Q2 | 51.33 Billion KRW | 1.5% |
| 2021 Q1 | 50.57 Billion KRW | 93.32% |
| 2020 Q1 | 23.39 Billion KRW | 0.86% |
| 2020 Q3 | 24.83 Billion KRW | 2.93% |
| 2020 Q4 | 26.15 Billion KRW | 5.32% |
| 2020 Q2 | 24.13 Billion KRW | 3.16% |
| 2020 FY | 27.07 Billion KRW | 13.51% |
| 2019 Q3 | 21.63 Billion KRW | 1.92% |
| 2019 Q2 | 21.22 Billion KRW | 2.61% |
| 2019 Q1 | 20.68 Billion KRW | 2.63% |
| 2019 FY | 23.85 Billion KRW | 18.35% |
| 2019 Q4 | 23.19 Billion KRW | 7.2% |
| 2018 Q2 | 5.54 Billion KRW | 5.64% |
| 2018 Q1 | 5.24 Billion KRW | -1.72% |
| 2018 Q4 | 20.15 Billion KRW | 278.48% |
| 2018 FY | 20.15 Billion KRW | 277.69% |
| 2018 Q3 | 5.32 Billion KRW | -3.88% |
| 2017 FY | 5.33 Billion KRW | -23.54% |
| 2017 Q2 | 8.19 Billion KRW | 12.51% |
| 2017 Q3 | 7.36 Billion KRW | -10.13% |
| 2017 Q4 | 5.33 Billion KRW | -27.54% |
| 2017 Q1 | 7.28 Billion KRW | 4.38% |
| 2016 Q3 | 4.59 Billion KRW | -14.39% |
| 2016 FY | 6.97 Billion KRW | 50.71% |
| 2016 Q1 | 5.09 Billion KRW | 10.13% |
| 2016 Q4 | 6.97 Billion KRW | 51.9% |
| 2016 Q2 | 5.36 Billion KRW | 5.24% |
| 2015 Q1 | 5.61 Billion KRW | 9.29% |
| 2015 Q4 | 4.63 Billion KRW | -17.21% |
| 2015 Q3 | 5.59 Billion KRW | 20.16% |
| 2015 Q2 | 4.65 Billion KRW | -17.04% |
| 2015 FY | 4.63 Billion KRW | -9.8% |
| 2014 Q1 | 17.57 Billion KRW | 2.17% |
| 2014 FY | 5.13 Billion KRW | -70.15% |
| 2014 Q3 | 9.67 Billion KRW | -2.98% |
| 2014 Q2 | 9.97 Billion KRW | -43.26% |
| 2014 Q4 | 5.13 Billion KRW | -46.92% |
| 2013 Q1 | 15.65 Billion KRW | 0.0% |
| 2013 Q2 | 21.73 Billion KRW | 38.83% |
| 2013 FY | 17.19 Billion KRW | 0.0% |
| 2013 Q3 | 20.11 Billion KRW | -7.44% |
| 2013 Q4 | 17.19 Billion KRW | -14.49% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 5.54 Billion KRW | -866.819% |
| ST Pharm Co.,Ltd. | 192.08 Billion KRW | 72.082% |
| ABL Bio Inc. | 43.93 Billion KRW | -22.047% |
| Cellid, Co., Ltd. | 11.99 Billion KRW | -347.067% |